ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION

Aim. To analyze the structure of expenses associated with warfarin dose adjustment and international normalized ratio (INR) control for patients with atrial fibrillation (AF) per 1 year of treatment. Material and methods. AF prevalence rate was calculated according to the large population studies da...

Full description

Bibliographic Details
Main Authors: Yu. B. Belousov, I. S. Yavelov, D. Yu. Belousov, E. V. Afanasieva
Format: Article
Language:English
Published: Столичная издательская компания 2016-01-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/899
_version_ 1797232304604577792
author Yu. B. Belousov
I. S. Yavelov
D. Yu. Belousov
E. V. Afanasieva
author_facet Yu. B. Belousov
I. S. Yavelov
D. Yu. Belousov
E. V. Afanasieva
author_sort Yu. B. Belousov
collection DOAJ
description Aim. To analyze the structure of expenses associated with warfarin dose adjustment and international normalized ratio (INR) control for patients with atrial fibrillation (AF) per 1 year of treatment. Material and methods. AF prevalence rate was calculated according to the large population studies data. The study was performed based on methodology for Cost of Illness evaluation. Expenses associated with INR monitoring within the obligatory medical insurance program were calculated based on the general tariff agreement for 2011 year for one of the territorial subject of Russia. Expenses associated with INR monitoring in outpatient departments of university clinics and commercial laboratories were calculated based on price list of respective institutes. Expenses associated with INR monitoring in case of self-monitoring were calculated based on expenses for portable coagulometer and test strips purchasing.  Results. Around 539 000 people in Russia are needed warfarin therapy and associated continuous INR monitoring. In the obligatory medical insurance program the cost of warfarin is less than 1% of total costs and the direct costs of treatment and control of nearly 4 058.12 RUR/person per year , in university clinics, respectively , 0.03%, and 13 019.05 RUR, in case of self-monitoring - 0.01-0.05% and from 40 405.00 (in the first year) to7 404.98 RUR (in the consequent years), respectively. Conclusion. The cost of warfarin, regardless of the INR monitoring approach is less than 1% of the total cost of the treatment with therapy efficacy and safety control.
first_indexed 2024-03-08T14:04:08Z
format Article
id doaj.art-89c2e0e9a02c4bbc956bda8aee75e128
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-04-24T15:58:09Z
publishDate 2016-01-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-89c2e0e9a02c4bbc956bda8aee75e1282024-04-01T07:43:30ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-017556156610.20996/1819-6446-2011-7-5-54-56898ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATIONYu. B. Belousov0I. S. Yavelov1D. Yu. Belousov2E. V. Afanasieva3The Russian National Research Medical University named after N.I. PirogovResearch Institute of Physico-Chemical MedicineCenter of pharmacoeconomic studiesCenter of pharmacoeconomic studiesAim. To analyze the structure of expenses associated with warfarin dose adjustment and international normalized ratio (INR) control for patients with atrial fibrillation (AF) per 1 year of treatment. Material and methods. AF prevalence rate was calculated according to the large population studies data. The study was performed based on methodology for Cost of Illness evaluation. Expenses associated with INR monitoring within the obligatory medical insurance program were calculated based on the general tariff agreement for 2011 year for one of the territorial subject of Russia. Expenses associated with INR monitoring in outpatient departments of university clinics and commercial laboratories were calculated based on price list of respective institutes. Expenses associated with INR monitoring in case of self-monitoring were calculated based on expenses for portable coagulometer and test strips purchasing.  Results. Around 539 000 people in Russia are needed warfarin therapy and associated continuous INR monitoring. In the obligatory medical insurance program the cost of warfarin is less than 1% of total costs and the direct costs of treatment and control of nearly 4 058.12 RUR/person per year , in university clinics, respectively , 0.03%, and 13 019.05 RUR, in case of self-monitoring - 0.01-0.05% and from 40 405.00 (in the first year) to7 404.98 RUR (in the consequent years), respectively. Conclusion. The cost of warfarin, regardless of the INR monitoring approach is less than 1% of the total cost of the treatment with therapy efficacy and safety control.https://www.rpcardio.online/jour/article/view/899atrial fibrillationwarfarinthe cost of illness
spellingShingle Yu. B. Belousov
I. S. Yavelov
D. Yu. Belousov
E. V. Afanasieva
ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
Рациональная фармакотерапия в кардиологии
atrial fibrillation
warfarin
the cost of illness
title ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
title_full ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
title_fullStr ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
title_full_unstemmed ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
title_short ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
title_sort analysis of direct costs associated with the use of warfarin in patients with atrial fibrillation
topic atrial fibrillation
warfarin
the cost of illness
url https://www.rpcardio.online/jour/article/view/899
work_keys_str_mv AT yubbelousov analysisofdirectcostsassociatedwiththeuseofwarfarininpatientswithatrialfibrillation
AT isyavelov analysisofdirectcostsassociatedwiththeuseofwarfarininpatientswithatrialfibrillation
AT dyubelousov analysisofdirectcostsassociatedwiththeuseofwarfarininpatientswithatrialfibrillation
AT evafanasieva analysisofdirectcostsassociatedwiththeuseofwarfarininpatientswithatrialfibrillation